Program
barzolvolimab
Also written as “CDX-0159” and “Barzolvolimab”.
Its studies are mostly in Chronic Urticaria · Prurigo · Dermatitis, Atopic · Eosinophilic Esophagitis, led by Celldex Therapeutics.
Furthest: phase 3, since May 31, 202414 company-led studies, 6 open or runningNext primary completion: Jun 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Celldex Therapeutics | 146 open or running | phase 3since May 31, 2024 | Oct 29, 2019 | Jun 2028phase 3 · NCT07266402 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2019First study: phase 1 study in Healthy SubjectsFirst studyNCT04146129 · 32 enrolled · United States
- Aug 31, 2020Phase 1 study in Chronic UrticariaNCT04538794 · 45 enrolled · United States, Germany
- Sep 8, 2020Phase 1 study in Cold UrticariaNCT04548869 · 41 enrolled · Germany
- Jun 22, 2021Phase 1 study in Prurigo NodularisNCT04944862 · 24 enrolled · United States, Germany, Poland
- Jul 29, 2021Phase 1 study in Healthy SubjectsNCT05031624 · 32 enrolled · United States
- May 5, 2022Phase 2 study in Chronic UrticariaNCT05368285 · 208 enrolled · United States, Bulgaria, Estonia and more
- Jun 1, 2022Phase 2 study in Chronic Inducible UrticariaNCT05405660 · 196 enrolled · United States, Bulgaria, Estonia and more
- Mar 7, 2023Phase 2 study in Eosinophilic EsophagitisNCT05774184 · 86 enrolled · United States, Australia, Canada and more
- Mar 27, 2024Phase 2 study in Prurigo NodularisNCT06366750 · 140 enrolled · United States, Canada, Croatia and more
- May 31, 2024Phase 3 study in Chronic UrticariaNCT06445023 · 963 enrolled · United States, Argentina, Belgium and more
- Jun 7, 2024Phase 3 study in Chronic UrticariaNCT06455202 · 976 enrolled · United States, Australia, Bulgaria and more
- Dec 9, 2024Phase 2 study in Dermatitis, AtopicNCT06727552 · 131 enrolled · United States
- Nov 19, 20252 phase 3 studiesNCT07266402, NCT07256392
Ahead
- Jun 2028Primary completion: phase 3 study in Chronic Inducible UrticariaNCT07266402
- Sep 2028Primary completion: phase 3 study in Chronic UrticariaNCT07256392
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07256392Chronic Urticaria · United States, Argentina, Australia and more | 3 | By invitation | Sep 2028 | 1,370 |
| NCT07266402Chronic Inducible Urticaria · United States, Germany, Lithuania and more | 3 | Recruiting | Jun 2028 | 240 |
| NCT06727552Dermatitis, Atopic · United States | 2 | Active, not recruiting | May 6, 2026 | 131 |
| NCT06455202Chronic Urticaria · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Aug 4, 2026 | 976 |
| NCT06445023Chronic Urticaria · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Aug 12, 2026 | 963 |
| NCT06366750Prurigo Nodularis · United States, Canada, Croatia and more | 2 | Active, not recruiting | Mar 17, 2026 | 140 |
| NCT05774184Eosinophilic Esophagitis · United States, Australia, Canada and more | 2 | Completed | Jun 4, 2025 | 86 |
| NCT05405660Chronic Inducible Urticaria · United States, Bulgaria, Estonia and more | 2 | Completed | Jun 12, 2024 | 196 |
| NCT05368285Chronic Urticaria · United States, Bulgaria, Estonia and more | 2 | Completed | Sep 28, 2023 | 208 |
| NCT05031624Healthy Subjects · United States | 1 | Completed | Jan 14, 2022 | 32 |
| NCT04944862Prurigo Nodularis · United States, Germany, Poland | 1 | Completed | Jul 31, 2023 | 24 |
| NCT04548869Cold Urticaria · Germany | 1 | Completed | Dec 16, 2022 | 41 |
| NCT04538794Chronic Urticaria · United States, Germany | 1 | Completed | Jan 17, 2023 | 45 |
| NCT04146129Healthy Subjects · United States | 1 | Completed | Apr 6, 2020 | 32 |
How it is read
Names in the registry
- “barzolvolimab”, 7 entries
- “CDX-0159”, 5 entries
- “Barzolvolimab”, 2 entries
Conditions, from the studies’ own filings
- Chronic Urticaria, 5 studies
- Prurigo, 2 studies
- Dermatitis, Atopic, 1 study
- Eosinophilic Esophagitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.